OncoGenex begins enrolment in Rainier Phase II pancreatic cancer trial

OncoGenex Pharmaceuticals has started enrolment in the investigator-sponsored Rainier Phase II trial of apatorsen (OGX-427) in combination with Abraxane plus gemcitabine in patients with metastatic pancreatic cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news